Ocugen, Inc. (NASDAQ:OCGN)
| Market Cap | 332.40M-44.8% |
| Revenue (ttm) | 4.58M-3.7% |
| Net Income | -81.81M-43.7% |
| EPS | -0.25-27.9% |
| Shares Out | 339.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,018,689.592 |
| Open | 1.01 |
| Previous Close | 1.00 |
| Day's Range | 0.96 - 1.01 |
| 52-Week Range | 0.96 - 2.73 |
| Beta | 2.27 |
| Analysts | Buy |
| Price Target | 5.00(+410.10%) |
| Earnings Date | Nov 4, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About OCGN
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$OCGN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in OCGN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by OCGN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
OCGN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
OCGN Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Collaborative Arrangements | $1.49M | 50.89% |
| Facilities and other support costs | $842.00K | 28.80% |
| Other | $594.00K | 20.31% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New OCGN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to OCGN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in OCGN
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $13.54M |
| XBIState Street SPDR S&P Biotech ETF | $11.80M |
| IWMiShares Russell 2000 ETF | $9.09M |
| VXFVanguard Extended Market ETF | $5.23M |
| VTWOVanguard Russell 2000 ETF | $2.61M |
| IWOiShares Russell 2000 Growth ETF | $2.23M |
Estimated from each fund’s disclosed top holdings × AUM
OCGN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from OCGN’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score